NX-1207 2.5 mg + NX-1207 15 mg
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Feb 21, 2012 → Oct 21, 2015
NCT ID
NCT01620515About NX-1207 2.5 mg + NX-1207 15 mg
NX-1207 2.5 mg + NX-1207 15 mg is a phase 2 stage product being developed by Nymox Pharmaceutical for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01620515. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01620515 | Phase 2 | Completed |
Competing Products
20 competing products in Prostate Cancer